Atopic Dermatitis, commonly called Eczema, affects millions globally with cases rising in India. Misunderstandings about its ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

The company has previously reported positive data for its PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

When childhood atopic dermatitis persists into adulthood, the large reduction in quality of life suggests that the price of ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...